Bone-modifying agents may alter biochemical presentation and operative findings in primary hyperparathyroidism.

Authors

Abigail C Chmiel, Genesys Giraldo, Caroline Jones, Meredith Freeman, Naga M Yalla, William E Gillanders, John A Olson, Taylor C Brown

Published in

Surgery. Pages 110587. Sep 01, 2026. Epub Sep 01, 2026.

Abstract

Primary hyperparathyroidism is closely linked to bone metabolism, leading to increased bone resorption and osteoporosis. Bone-modifying agents are commonly used to mitigate bone loss by altering calcium metabolism; however, their effect on the biochemical and operative presentation of primary hyperparathyroidism has not been well characterized. This study evaluates the association between bone-modifying agent use, biochemical markers, and operative findings among patients with primary hyperparathyroidism.
A retrospective review was conducted of patients who underwent parathyroidectomy for primary hyperparathyroidism between 2019 and 2025 at a single tertiary referral center. A history of bone-modifying agent use and bone disease was assessed. Descriptive statistics and univariate analyses were performed to evaluate associations between bone-modifying agent use and the biochemical and operative phenotypes of primary hyperparathyroidism.
A total of 899 patients met inclusion criteria, of whom 187 (20.8%) had a history of bone-modifying agent use. Patients with bone-modifying agent use were more likely to be female (P < .001), White (P < .001), and older on average (70 vs 60 years, P < .001). Mean serum calcium levels (10.5 vs 10.9 mg/dL, P < .001) and mean parathyroid hormone levels (99.5 vs 119.7 pg/mL, P < .001) were lower among bone-modifying agent users. Multigland disease was more frequent in bone-modifying agent users (43% vs 32%, P = .03) as was bilateral neck exploration (54% vs 45%, P = .033).
In patients undergoing parathyroidectomy for primary hyperparathyroidism, the use of bone-modifying agents is associated with a distinct biochemical profile and a higher prevalence of multigland disease. A more nuanced understanding of the relationship between bone-modifying agents and the pathophysiology and surgical presentation of primary hyperparathyroidism could inform preoperative planning and guide individualized evaluation strategies in this patient population.

PMID:
42791099
Bibliographic data and abstract were imported from PubMed on 26 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.